mutations provided the fact that, as stated underneath, CLL therapy is based to the presence or absence of such mutations. The present consensus is usually that, besides clonal mutations, subclonal mutations that has a variant allelic frequency ranging from 5 to ten% (and so down below the threshold of detection by typical molecular strategies) is